Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells

Baran Y., Ural A. U., GÜNDÜZ U.

HEMATOLOGY, cilt.12, sa.6, ss.497-503, 2007 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 12 Sayı: 6
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1080/10245330701384179
  • Dergi Adı: HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.497-503
  • Abdullah Gül Üniversitesi Adresli: Hayır

Özet

A major advancement in the treatment of chronic myeloid leukemia (CML) has been the development of imatinib, which has shown striking activity in the chronic phase and the accelerated phase, but less so in the blast phase of the disease. Despite high rates of hematologic and cytogenetic responses to therapy, the emergence of resistance to imatinib has been recognized as a major problem in the treatment of patients with CML.